Lifecore Biomedical's Share Price Down 30% Over Five Years, Revenue Growth Weaker Than Most Pre-Profit Companies.

Lifecore Biomedical's stock price has fallen 30% in the last five years and 12% in the last 90 days. Despite not making a profit in the last twelve months, the company reduced its trailing twelve-month revenue by 24% each year, which is a weaker result than most pre-profit companies report. The share price fall of 5% compound over five years is well justified by the fundamental deterioration.